BIO89-100-131 The ENLIGHTEN-Fibrosis Study Pro00115755. A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis.